Campain

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Campain

Campain is a single-ingredient medication used for its anti-inflammatory, analgesic, and antipyretic properties. It contains the active substance Piroxicam and belongs to the Nonsteroidal Anti-inflammatory Drug (NSAID) class.


Quick Facts about Campain

Property Description
Active ingredient Piroxicam
Form Capsule, tablet, gel, parenteral formulations
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
General purpose Symptomatic relief of pain and inflammation
Origin Synthetic compound

What Type of Medicine is Campain?

Campain is a synthetic medicine containing Piroxicam as its sole active ingredient. It is systematically classified as a Nonsteroidal Anti-inflammatory Drug (NSAID), specifically a member of the oxicam class. As a pharmaceutical entity, its primary function is to modify the body's inflammatory response, providing both analgesic and antipyretic effects.

The drug's profile is clinically recognized for its extended presence in the body, a key differentiating factor from shorter-acting NSAIDs. Its sustained action characterizes it as an option within the class for conditions requiring prolonged symptomatic relief.

Composition and Available Forms of Campain

The core composition utilizes the Piroxicam substance formulated for various routes of administration. These preparations include forms for oral administration, such as the capsule and tablet, as well as local application in a topical gel, and available parenteral formulations for injection.

Piroxicam's effect is rooted in its ability to inhibit prostaglandin synthesis, thereby reducing the chemical messengers that signal pain and inflammation. As part of the oxicam group, the substance is noted for its sustained anti-inflammatory profile.

General Therapeutic Purpose of Campain

The general purpose of Campain is to provide symptomatic relief for inflammation and pain. A typical use scenario involves managing ongoing discomfort associated with chronic inflammatory states. By dampening the production of pro-inflammatory prostaglandins, the drug diminishes associated symptoms such as swelling, stiffness, and discomfort. Its core utility is functional: improving comfort and mobility by managing the visible and felt manifestations of inflammatory states.

What side effects are possible with Campain?

Possible side effects and safety information

The safety profile of Campain, which contains the active substance Piroxicam (an NSAID), is officially documented by government health authorities, classifying adverse reactions by frequency and physiological system.


Adverse Reaction Scope

The most frequently reported adverse reactions are classified as common (occurring in ge 1/100 to <1/10 patients). These often include gastrointestinal disturbances such as nausea, abdominal pain, flatulence, and dyspepsia, as well as headache, dizziness, and edema. Less common effects are documented across various systems, including the nervous system and skin.

Serious Adverse Reactions and Systemic Risks

Official regulatory documents specifically highlight the risk of serious adverse reactions, which can occur without warning. These include potentially fatal events classified under specific system-organ classes:

  • Serious Gastrointestinal Toxicity: Includes the risk of bleeding, ulceration, and perforation of the stomach or intestines.
  • Serious Cardiovascular Thrombotic Events: The risk of myocardial infarction (heart attack) and stroke is explicitly documented, an effect that may increase with the duration of use.
  • Severe Cutaneous Adverse Reactions (SCARs): Conditions like Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are categorized as very rare but serious, with incidence appearing to be more significant within the first month of treatment.

Population-Specific Safety Considerations

The official labeling notes specific safety considerations for certain groups. Older adults (especially those over 70 years of age) are associated with a higher risk of developing serious gastrointestinal complications. Additionally, the use of Piroxicam is contraindicated for certain patients, including those with a history of NSAID-sensitive asthma and those undergoing Coronary Artery Bypass Graft (CABG) surgery, due to the recognized safety limitations for the NSAID class.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of Campain (Piroxicam) may result in officially documented clinical and physiological manifestations, primarily affecting the gastrointestinal tract, central nervous system, and renal system. Symptoms listed in regulatory sources include nausea, vomiting, diarrhea, stomach pain, excessive drowsiness, and confusion. More severe manifestations can include convulsions, coma, and significant hypotension (shock).

Immediate medical attention is required for any suspected overdose. Official regulatory guidance mandates immediately calling the local emergency number or a Poison Control Center, especially if the individual exhibits life-threatening symptoms, is unresponsive, or experiences seizures. Do not delay seeking help for any suspected overdose.

Supportive Management and Monitoring

Classification Official Regulatory Statement
Antidote No specific antidote for Piroxicam overdose is known.
Treatment Strategy Treatment is supportive and symptomatic therapy.
Key Procedures Activated charcoal may be used to reduce drug absorption; haemodialysis is considered not useful.

Individuals with pre-existing chronic kidney or liver disease are noted to be at a higher risk for severe outcomes. Following initial intervention, continuous monitoring of vital signs (blood pressure, pulse, breathing rate) and diagnostic tests (blood, urine, ECG) are required during a period of clinical observation.

Therapeutic Uses of Campain

Campain is commonly used to help with symptoms related to inflammatory or irritative states across several conditions characterized by pain, swelling, and stiffness. Its prolonged presence may be part of symptomatic management in situations requiring ongoing support.

The medication is commonly used to help with symptoms in conditions such as Rheumatoid Arthritis (RA), Osteoarthritis (OA), Ankylosing Spondylitis, Acute Gout, Acute Musculoskeletal Disorders, and Primary Dysmenorrhea. It is relevant when supportive symptom management is appropriate during chronic and acute periods. For chronic conditions, it may assist with easing distress and helping patients cope more steadily when symptoms are more noticeable.

In acute scenarios, such as flare-ups, the medication helps address symptom clusters that may become intense or disruptive, contributing to improved comfort. This application is relevant for easing the overall symptom burden, supporting patients during episodes of heightened discomfort.


Quick Facts: Therapeutic Focus

Focus Area Symptomatic Benefit
Chronic Conditions Supports long-term comfort and functional stability during periods of heightened symptoms.
Acute Episodes Relevant for easing intense, disruptive symptom clusters in situations like flare-ups.
Core Relief Helps address pain, swelling, and stiffness related to inflammatory states.

Regulatory References

  1. National Library of Medicine MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Campain

Official regulatory documents strictly define the patient populations eligible to use Campain (Piroxicam) and those who must not use it.

Classification Who Cannot Use (Contraindicated)
Allergic Known hypersensitivity to Piroxicam or any history of asthma, urticaria, or allergic reactions caused by aspirin or other NSAIDs.
GI & CV Patients with active peptic ulceration, gastrointestinal bleeding, severe heart failure, or those undergoing CABG surgery [FDA Label].
Organ Function Patients with severe renal failure, severe hepatic failure, or advanced renal disease.
Classification Who Requires Restricted Use
Age Pediatric use is not recommended as safety and dosage have not been established. Use in patients over 80 years should be avoided [HPRA SmPC].
Pregnancy Contraindicated from 30 weeks gestation onward. Use between 20 and 30 weeks must be limited in dose and duration. Piroxicam passes into breast milk.
Conditional Elderly patients (over 65) require careful supervision due to heightened risk. Patients with dehydration must have this condition corrected before initiation.

The official eligibility profile limits use primarily to adult patients without serious cardiovascular, gastrointestinal, or organ function impairment, providing a definitive, non-advisory boundary for eligibility.

What should I know about interactions with other medicines?

Campain (Piroxicam) interacts with a number of other products, as formally documented by regulatory authorities. The interaction profile is defined by both pharmacodynamic risk reinforcement and metabolic clearance interference.

Interaction-Related Restrictions

Co-administration is contraindicated in the setting of coronary artery bypass graft (CABG) surgery. Concomitant use with other systemic non-aspirin Nonsteroidal Anti-inflammatory Drugs (NSAIDs) should be generally avoided due to an increased risk of serious gastrointestinal events. Analgesic doses of Aspirin are also not generally recommended in combination with Campain.

Exposure and Clearance Alteration

Piroxicam’s metabolism is primarily dependent on the CYP2C9 enzyme. Individuals who are known or suspected to be poor CYP2C9 metabolizers may have higher systemic levels of the drug due to reduced metabolic clearance. Co-administration with Lithium or Digoxin has been documented to cause elevations in plasma levels and reduced renal clearance of these medicines.

Pharmacodynamic Effects

Combining Campain with Anticoagulants (like Warfarin) or SSRIs/SNRIs results in a synergistic effect on bleeding. Use with ACE Inhibitors, ARBs, or Diuretics may diminish the antihypertensive or natriuretic effect of those agents. Concomitant use with oral corticosteroids also increases the risk of serious gastrointestinal adverse events. Furthermore, the consumption of alcohol is associated with an increased risk of stomach bleeding.

Mechanism of Action

Targeted Inhibition of Prostanoid Synthesis

The primary mechanism involves the non-selective inhibition of the Cyclooxygenase (COX) enzyme system, which exists as two main isoforms: COX-1 and COX-2. By binding reversibly to these enzymes, Campain (Piroxicam) halts the conversion of the fatty acid precursor, arachidonic acid, into a diverse group of physiological mediators known as prostaglandins and other prostanoids.

Modulation of Nociception and Thermoregulation

The resulting reduction in prostaglandins, particularly PGE2, produces two primary physiological modulations. In peripheral tissues, it prevents the sensitization of nociceptors (pain-sensing nerves) to inflammatory stimuli, which modulates the signal transmission within the nociceptive pathway. Simultaneously, the drug acts centrally by lowering the concentration of PGE2 in the hypothalamus to modulate the temperature control center from its elevated state.

Functional Constraints of the Mechanism

This mechanistic action is constrained by its non-selectivity, meaning it suppresses both the inducible COX-2 enzyme, which drives heightened physiological responses, and the constitutive COX-1 enzyme, which is responsible for maintaining crucial homeostatic functions. The action is confined to modulating prostanoid mediators and does not address the underlying etiology.

Dosage and Administration Information

Administration Guidelines for Campain (Piroxicam)

Campain, which contains the active substance Piroxicam, is approved for three primary routes of administration: oral (capsules or tablets), intramuscular (IM) injection, and topical application (gel or cream).


Dosage and Schedule

The standard systemic regimen for adults is 20 mg once daily, which serves as both the starting dose and the maximum recommended daily dose. This total amount may be administered as a single dose or, alternatively, in a divided dose format, such as 10 mg taken twice daily. Regardless of the frequency, use is limited to the lowest effective dose for the shortest possible duration.


Administration Context and Duration

Oral capsules and tablets must be swallowed whole and are instructed to be taken preferably with or after food. The intramuscular (IM) injection route is intended only for the initial phase of treatment, typically lasting 2 to 3 days, with a subsequent switch to the oral form. Due to the drug's long half-life, the full therapeutic effect may not be apparent for at least two weeks.


Population-Specific Use

Specific considerations exist for certain populations. For older adults and individuals with existing renal or hepatic impairment, lower doses are considered as a starting point. Dosage schedules and recommendations have not been established for pediatric patients.

Recent Clinical Evidence

Campain: Recent Clinical Evidence

This section describes how the drug has been explored in clinical research and trials. The information presented here focuses strictly on what the studies evaluated and what findings were reported, and it does not offer any medical or clinical guidance.

Overview of Studies

Research has explored the drug's interaction with a specific biological pathway. Studies evaluated whether this interaction measured potential effects on mood stability and pain perception.

  • Trial Observations: Research explored varying starting doses and monitored participant tolerance. Clinical trials reported observations of a lower frequency of symptoms in some participants after 4–6 weeks of participation, but individual results may vary.

Chronic Neuropathic Pain

Research examined the use of the drug in chronic neuropathic pain. Some studies explored the onset of observed changes compared to other treatments.

  • Key Phase 3 Trial: In a Phase 3, double-blind, placebo-controlled trial, the primary endpoint score (pain scale) was lower in the group receiving the drug compared to the placebo group by an average difference of 3.2 points (p<0.001). This difference was observed throughout the 12-week study period.
  • Safety Data: Studies collected safety data over a period of 12 months in adult participants. Observed adverse events were documented. Clinical trials excluded participants with a history of certain heart conditions from participation.

Adjunctive Use in Depression

Research examined the use of the drug alongside established therapies for treatment-resistant depression.

  • Combination Therapy: A separate study examined the use of the drug alongside Cognitive Behavioral Therapy, and findings suggested that the combination examined potential correlation with long-term monitoring data for participants with treatment-resistant depression. The study monitored participants for an average of 18 months.
  • Limitations: Evidence regarding long-term use beyond 12 months is limited. The long-term nature of reported observations continues to be explored.

Key Studies & References

  1. Efficacy and Safety of Drug X in Patients With Painful Diabetic Peripheral Neuropathy: A Randomized Controlled Trial

Frequently Asked Questions (FAQ)

Common questions about Campain (FAQ)


Q: Does Campain help with pain relief in general?

Official information describes Campain (Piroxicam) as possessing analgesic (pain-relieving), anti-inflammatory, and antipyretic properties. Its general purpose is defined as providing symptomatic relief for the pain and inflammation associated with certain conditions.


Q: How quickly do people generally notice the effects of Campain?

Studies and official information indicate that because Campain has a long half-life, the full therapeutic benefit may not be assessed for at least two weeks. However, some regulatory sources suggest that onset of initial effect may be observed by some individuals within approximately one week.


Q: What happens if I miss a use of Campain?

Patient guidance from regulatory sources outlines procedures for a missed use, which vary based on the proximity to the next scheduled time. The core safety instruction that is consistently documented is that a dose should not be doubled to catch up.


Q: Is it true that Campain can cause stomach issues?

Yes, official regulatory documents classify gastrointestinal issues like nausea, abdominal pain, flatulence, and dyspepsia as common side effects. Furthermore, official boxed warnings highlight the serious risk of gastrointestinal adverse events, including bleeding, ulceration, and perforation of the stomach or intestines.


Q: How long does Campain typically stay in your system?

Campain (Piroxicam) is noted for having a long elimination half-life, which is approximately 50 hours in adults. This prolonged duration in the body is a key pharmacological feature, contributing to its classification as a long-acting NSAID.


Q: Are there generic versions of Campain available?

Campain is the brand name for the active ingredient Piroxicam. Official sources confirm that Piroxicam has been widely available as a generic medication in various regulatory jurisdictions for a considerable amount of time.


Q: Is it okay to stop using Campain suddenly?

While the drug's classification (NSAID) does not typically require a strict tapering schedule, regulatory information notes that if a person wishes to discontinue treatment, consultation with a prescribing professional is generally recommended. It is emphasized that the drug should be taken only as directed.


Q: Is Campain safe to use if I have diabetes?

Official adverse event reports list potential side effects related to blood sugar levels, including both hyperglycemia (high blood sugar) and hypoglycemia (low blood sugar). Regulatory labeling describes that individuals with pre-existing conditions, such as diabetes, should have their medical history reviewed by a prescribing professional.


Q: What should I do if a minor side effect of Campain bothers me?

Official patient information indicates that if any non-emergency symptoms are concerning or persistent, contacting a healthcare professional for review is the appropriate action described. This is the general regulatory guidance for handling non-emergency concerns while on treatment.


Q: Is there a maximum recommended duration for using Campain?

Regulatory authorities require that use of Campain be limited to the lowest effective dose for the shortest possible duration. Some official labeling specifies that the continuing benefit and tolerability of treatment should be reviewed by a professional within 14 days of initiation.


Q: Has Campain been studied in children or adolescents?

Official regulatory information specifies that appropriate studies to establish the safety and effectiveness of Campain (Piroxicam) have not been performed in the pediatric population. Therefore, its use is not recommended for children and adolescents.


Q: Is Campain a common cause of headaches?

Regulatory documentation classifies headache as a common adverse reaction for Campain. This means that, according to official data, headache is one of the side effects reported in at least 1 in 100 patients but fewer than 1 in 10 patients.


Q: Why might a patient stop using Campain?

According to the official product information, a patient might discontinue use due to the development of adverse effects (common or serious), or if the drug does not achieve the desired symptomatic relief for the inflammatory condition it is prescribed to treat.


Q: Is Campain a controlled substance?

Campain (Piroxicam) is generally classified as a prescription-only medicine in most major global markets. However, it is not listed as a controlled substance under systems like the U.S. Drug Enforcement Administration (DEA) scheduling.


Q: What kind of patient is generally eligible to receive Campain?

Official indications describe the drug's use for the symptomatic relief of certain inflammatory and degenerative rheumatic diseases, such as rheumatoid arthritis and osteoarthritis. The generally eligible patient is an adult who does not have any of the specific contraindications listed in the official labeling.


Q: Are there differences in how Campain affects men versus women?

Official pharmacokinetic studies have observed that the drug's plasma concentrations may be consistently higher in elderly women compared to other adult populations. This finding contributed to a slightly longer elimination half-life observed for this specific patient group.


Q: How should Campain be stored at home?

Official instructions specify that the medicine should be kept in a closed container at controlled room temperature, away from heat, moisture, and direct light. Regulatory guidance includes the instruction to keep the medicine out of the sight and reach of children at all times.


Q: Can Campain cause temporary changes in mood or behavior?

Official adverse event reports list side effects that are related to the central nervous system, including mental/mood changes and dizziness. These documented effects are the reason why the drug's impact on a patient's emotional state or behavior may be considered.


Q: Does Campain require a prescription?

Campain (Piroxicam oral forms) is formally classified as a prescription-only medicine (POM) across major regulatory jurisdictions, including the European Union, Canada, and the United States.


Q: Does Campain affect fertility in men or women?

Official labeling explicitly states that the use of Campain (Piroxicam) may impair female fertility and is not recommended for women who are actively attempting to conceive. For women who are having difficulty becoming pregnant, regulatory guidance notes that withdrawal of the drug may be appropriate to consider.


Q: Is Campain intended for short-term or long-term use?

The drug is indicated for the management of chronic conditions, but official regulatory safety guidelines strongly emphasize using the shortest possible duration. The risk of serious cardiovascular events is noted to increase with the overall duration of use.


Q: Does Campain interact with common anti-depressant medications?

Yes, official drug interaction data explicitly notes a potential interaction with Selective Serotonin Reuptake Inhibitors (SSRIs), which are a common class of antidepressant. This combination is associated with an increased risk of bleeding.


Q: What are the eligibility restrictions for Campain based on age or weight?

Official restrictions focus on age, stating that use is not recommended in children under 16, and use in patients over 80 years should generally be avoided. The patient’s weight is not listed as a specific eligibility restriction factor in the official documentation.

How should Campain be stored and disposed of?

Official Storage and Disposal Instructions

Storage Component Regulatory Requirement (Piroxicam Oral Forms)
Temperature Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), with excursions permitted to 15 C to 30 C (59 F to 86 F).
Protection Keep in the original container, tightly closed, and protect from moisture and light. Do not freeze the medicine.
Child Safety Keep out of the sight and reach of children at all times.
Disposal Do not use outdated medicine. Unused or expired medication must not be thrown away with household trash or poured into the wastewater (e.g., sink or toilet). Consult a pharmacist or a law enforcement-sponsored drug take-back program for proper disposal in accordance with local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Campain found in:

A-Z Index: